Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;12(3):204-10.
doi: 10.1111/j.1477-2574.2009.00150.x.

A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database

May Piperdi  1 , Theodore P McDade, Joon K Shim, Bilal Piperdi, Sidney P Kadish, Mary E Sullivan, Giles F Whalen, Jennifer F Tseng
Affiliations

A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database

May Piperdi et al. HPB (Oxford). 2010 Apr.

Abstract

Background: Recent studies have shown adjuvant therapy improves outcomes from pancreatic cancer (PC). This study investigates receipt and timing of PC treatments, and association with outcomes.

Methods: The analysis cohort consisted of patients with newly-diagnosed PC at a single institution over 5 years. Primary Endpoints were (i) receipt of recommended therapy, and (ii) overall survival (OS).

Results: Among 102 patients, 52 underwent resection. Out of 36 localized resected and 16 locally advanced resected (LAR) patients, 26 and 13, respectively, received adjuvant therapy. Six of the latter group received neoadjuvant therapy. Median OS for resected patients was 15.7 months (range 0.6-51.4), compared with 7.7 for unresected patients (range 0.4-32.0) (P < 0.001), and 14.0 months for patients with resection alone (range 0.6-24.4) vs. 16.1 for patients who also received adjuvant therapy (range 3.2-51.4) (P= 0.027). Out of 46 patients undergoing up-front resection, 33 had R0 surgical margins. For the six LAR patients undergoing neoadjuvant therapy, all margins were R0.

Conclusion: After resection, a substantial proportion of patients do not receive adjuvant therapy, and have worse survival. In this study, neoadjuvant treatment increased both the proportion of patients receiving all components of recommended therapy and the R0 resection rate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of resected (RT) pancreatic adenocarcinoma patients by treatment approach
Figure 2
Figure 2
Overall Kaplan-Meier survival of patients with pancreatic adenocarcinoma reffered for surgical evaluation for (A) resected versus unresected patients and (B) resected patients with or without chemo-radiation
See this image and copyright information in PMC

References

    1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30. - PubMed
    1. Evans DB, Abbruzzese JL, Willett CG. Cancer of the pancreas. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer – Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams and Wilkins; 2001. pp. 1126–1148.
    1. deCastro SMM, Biere SSAY, LaGarde SM, Busch ORC, van Gulik TM, Gouma DJ. Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreas. Br J Surg. 2009;96:417–423. - PubMed
    1. Pisters PW, Wolff RA, Crane CH, Evans DB. Combined-modality treatment for operable pancreatic adenocarcinoma. Oncology (Williston Park) 2005;19:393–404. 409; discussion 409–410, 412–416. - PubMed
    1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049–1057. - PubMed

MeSH terms